(Q57165945)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

5

Jerome H Kim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

7

Matthias J Schnell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

6

James P McGettigan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Robert McLinden

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Philip M McKenna

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Martin L Koser

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

English

0 references

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

number of pages

12

1 reference

inferred from page(s)

published in

Virology

0 references

volume

331

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

82-93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

The challenge of viral reservoirs in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Neutralizing antibodies against HIV -- back in the major leagues?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Development of a DNA-MVA/HIVA vaccine for Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Effector and memory T-cell differentiation: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

T cell responses and viral escape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

7 January 2021

HIV vaccines 1983-2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Design and tests of an HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Infectious rabies viruses from cloned cDNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Vaccines against intracellular infections requiring cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Will we be able to 'spot' an effective HIV-1 vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

7 January 2021

Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

7 January 2021

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

7 January 2021

Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

7 January 2021

Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

7 January 2021

Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.018

7 January 2021

10.1016/J.VIROL.2004.10.018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15582655%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference